ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2017 Financial Results
To access the live call by phone, dial 719-325-4907; the conference ID
is 6498153. The call also may be accessed through the Investors section
of the Company's website, www.immunogen.com.
Following the live webcast, a replay of the call will be available at
the same location through
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. The Company's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in a Phase 1b/2 trial in combination regimens for earlier-stage disease. ImmunoGen has three additional clinical-stage product candidates, two of which are being developed in collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC technology is also used in Roche's marketed product, Kadcyla®, and in programs in development by Amgen, Bayer, Biotest, CytomX,
Kadcyla® is a registered trademark of
FTI Consulting, Inc.
Robert Stanislaro, 212-850-5657
News Provided by Acquire Media